

**Form PTO-1449 Substitute U.S. Department of Commerce  
Patent and Trademark Office**

Application Number	10/037,415
Filing Date	January 4, 2002
First Named Inventor	David Baltimore
Art Unit	1636
Examiner Name	D. Guzo
Attorney Docket No.	75723-ZB/JPW/GJG

**INFORMATION DISCLOSURE STATEMENT**  
(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	1	2007-0207943	09-06-2007	Ebner et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	Ariad Pharmaceuticals v. Dudas, Civil Action No. 1:06cv679 (U.S. Dist. Ct.: Eastern District of Va: Alexandria): Memorandum of Points and Authorities In Support of Motion To Dismiss Or In the Alternative For Summary Judgment and Opposition to Plaintiff's Motion For Summary Judgment, pp1-30;	
	3	Harant et al., (1997) "1alpha,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression," Eur. J. Biochem., 250:63-71;	
	4	Kunin et al., (2002) "Reach-Through Claims in the Age of Biotechnology," Am. U.L. Rev., 51:609-638;	
	5	Meyer et al., (1997) "Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation," FEBS Lett., 413:354-358;	
	6	Roman-Blas et al., (2006) "NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis," Osteoarthritis Cartilage, 14:839-48; and	
	7	Yamamoto et al., (2005) "Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study," Inflamm. Bowel Dis., 11:589-596.	

EXAMINER  
SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David Baltimore, et al.  
Serial No.: 10/037,415  
Filed: January 4, 2002  
Exhibit A of August 8, 2008 sIDS